These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37919738)

  • 21. OncoVEX
    Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
    Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
    Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
    Chesney JA; Puzanov I; Collichio FA; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan T; Hauschild A; Lebbé C; Joshi H; Snyder W; Mehnert JM
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
    Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
    J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis.
    Li Z; Jiang Z; Zhang Y; Huang X; Liu Q
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
    Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
    Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Talimogene laherparepvec monotherapy for head and neck melanoma patients.
    Franke V; Stahlie EHA; Klop WMC; Zuur CL; Berger DMS; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Melanoma Res; 2023 Feb; 33(1):66-70. PubMed ID: 36454284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
    Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
    J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
    Ott PA; Hodi FS
    Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
    Barker CA; D'Angelo SP; Wasilewski G; Steckler AM; Lian M; Zhang Z; Chapman PB; Shoushtari AN; Ariyan CE
    Radiother Oncol; 2024 Nov; 200():110478. PubMed ID: 39159678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.
    Franke V; Stahlie EHA; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    J Immunother; 2022 Jul-Aug 01; 45(6):263-266. PubMed ID: 35580326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
    Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.
    Stahlie EHA; Mulder EEAP; Reijers S; Balduzzi S; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; Grunhagen DJ; van Akkooi ACJ
    Crit Rev Oncol Hematol; 2022 Jul; 175():103705. PubMed ID: 35569723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.